iMATRIX-cobi is the first study to investigate the safety, pharmacokinetics, and therapeutic activity of cobimetinib in pediatric and young adult patients with previously treated solid tumors.

The single-agent safety profile of cobimetinib in pediatric patients was similar to that observed in adults, but steady state mean exposure of cobimetinib at the RP2D was approximately 50 % lower than in adults receiving the approved dose.

A best objective response of partial response was seen in three patients with LGG; combination regimens may further improve response rates in this patient population.